Dr. Dave Singh, Expert and Researcher in Epigenetics and Sleep Apnea Treatment, to Speak at the International Conference on Sleep Disorders
Published author of clinical research papers to speak at five conferences in 2018
DENVER (January 30, 2018) – Vivos, a leading provider of services and devices that treat and potentially resolve mild to moderate sleep apnea and improve the overall health of patients, announced today that Dr. Dave Singh, DDS, PhD, DDsc will be featured as a keynote speaker at several medical, dental and sleep conferences in 2018.
Dr. Singh serves as president of Vivos, as well as on the company’s board of directors and its clinical advisory board. He has recently published two clinical research papers – January’s article in the Journal of Craniomandibular and Sleep Practice on the efficacy of biomimetic oral appliance therapy to treat and resolve obstructive sleep apnea (OSA); and an upcoming 2018 article in the Journal of Sleep Disorders: Treatment and Care.
His upcoming speaking schedule includes:
- Keynote at the American Sleep and Breathing Academy Annual Conference, April, 2018
- Keynote at the 29thInternational Conference on Sleep Disorders and Medicine July 2018
- Keynote at the 3rdEuropean Otolaryngology-ENT Surgery Conference, October 2018
- Keynote at the Neuropsychiatry and Sleep Medicine Conference, September 2018
- Keynote at the 2nd Global Summit on Otolaryngology, November 2018
“Sharing my work with so many prestigious medical and dental audiences is an opportunity to further the critical message about the benefits of biomimetic oral appliance therapy to treat OSA,” said Dr. Singh. “We’ve got to educate the professionals who are daily meeting and consulting with thousands of sufferers and patients whose health and quality of life depends on getting proper treatment of obstructive sleep apnea and sleep-disordered breathing.”
For more information about Vivos, please click here.
Media Contact: Shannon Michael, SnappConner PR, firstname.lastname@example.org
Founded in 2016, Vivos Therapeutics combines breakthrough technology for specially designed oral appliances with proprietary clinical protocols for obstructive sleep apnea (OSA) treatment that can restore and enhance the human airway. Because its patented FDA Class I and II medical devices are thought to be the first treatment that addresses the root causes of OSA, Vivos can improve the airway so that further clinical intervention may no longer be required in some cases. Other treatments for this insidious and dangerous condition require lifetime treatment, which has a significant impact on U.S. healthcare costs. Because the Vivos System is all-natural, non-invasive and non-pharmaceutical, many more patients will be able to receive treatment from the 750+ (and growing) independent providers who have been trained and certified in the Vivos methodology and who have already treated more than 8,000 patients. The company also is creating Vivos Breathing Wellness Centers in major metro areas, working with licensed and trained local medical and dental professionals. For more information, visit vivoslife.com.